Esokalli Delay Performance Gel

For the diagnostic evaluation of pituitary function (Growth Hormone Reserve Test), the standard adult dose of Arginine Hydrochloride is typically 30 grams. This is administered as a 10% intravenous infusion (300 mL) over a period of 30 minutes. Healthcare providers will typically draw blood samples at specific intervals (e.g., -30, 0, 30, 60, 90, 120, and 150 minutes) to measure the plasma growth hormone levels.

In the context of nutritional supplementation or metabolic support, oral doses can vary significantly, often ranging from 2 grams to 6 grams per day, divided into two or three doses. However, these doses are not standardized for medical treatment and should only be taken under the guidance of a physician.

In pediatric patients, the dose for growth hormone provocation testing is strictly weight-based to ensure safety and accuracy. The standard dose is 0.5 grams per kilogram of body weight (0.5 g/kg). The total dose should not exceed the maximum adult dose of 30 grams. For example, a child weighing 20 kg would receive 10 grams of Arginine (100 mL of a 10% solution) infused over 30 minutes.

Renal Impairment

Arginine should be used with extreme caution in patients with renal disease. Because Arginine is a nitrogen-containing compound, its metabolism increases the nitrogen load on the kidneys. In patients with significant renal insufficiency, the risk of hyperkalemia (high potassium) and metabolic acidosis is substantially increased. Dosage reductions or avoidance may be necessary, and frequent monitoring of electrolytes is mandatory.

Hepatic Impairment

Patients with severe hepatic impairment, such as cirrhosis, may have difficulty processing the ammonia generated during arginine metabolism. While Arginine is used to treat certain urea cycle issues, in general liver disease, it must be used with caution to avoid electrolyte imbalances and potential encephalopathy.

Elderly Patients

Clinical studies of Arginine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, because elderly patients are more likely to have decreased renal function, dose selection should be cautious, usually starting at the low end of the dosing range.

For diagnostic purposes, Arginine is administered only by healthcare professionals in a hospital or specialized clinic.

• Preparation: The solution should be clear and the container undamaged.
• Administration: It is given as a slow intravenous infusion. Rapid infusion can cause local irritation, nausea, or vomiting.
• Oral Supplementation: If prescribed for oral use, it is generally recommended to take Arginine with food to minimize gastrointestinal upset. It should be swallowed whole with a full glass of water.
• Storage: Intravenous Arginine should be stored at room temperature (25°C/77°F) and should not be frozen. If the solution becomes cold and crystals form, it may be warmed gently before use.

Since clinical Arginine is typically administered as a single diagnostic infusion, a missed dose is unlikely. If you are taking Arginine as a daily supplement and miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up.

An overdose of Arginine can lead to serious metabolic complications. Symptoms of overdose may include severe metabolic acidosis, rapid breathing (hyperventilation), tremors, or even coma. In the event of an overdose during an infusion, the infusion must be stopped immediately. Treatment is supportive and focuses on correcting electrolyte imbalances and neutralizing the acid load, often using sodium bicarbonate or other alkalizing agents.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop a prescribed regimen without medical guidance.

Arginine is generally well-tolerated when administered at recommended diagnostic doses, but some patients may experience immediate reactions during or shortly after the infusion. Common side effects include:

• Nausea and Vomiting: This is the most frequently reported side effect. It often occurs if the infusion rate is too rapid. Patients may feel a sudden wave of queasiness or the urge to vomit.
• Flushing: A sensation of warmth, redness, or tingling in the face, neck, or upper chest is common due to the vasodilatory effects of Arginine.
• Headache: Some patients report a mild to moderate headache during the infusion, which typically resolves shortly after the procedure ends.
• Local Irritation: Pain, redness, or swelling at the site of the intravenous injection occurs in roughly 10% of patients.

• Numbness or Tingling: Also known as paresthesia, some patients feel 'pins and needles' in their extremities.
• Dizziness: A feeling of lightheadedness or vertigo may occur, especially when standing up quickly after the infusion.
• Abdominal Cramping: Some patients experience bloating or mild stomach pain.
• Heartburn: A burning sensation in the chest or throat, particularly with oral formulations.

• Rash or Urticaria: Small, itchy red bumps or hives may appear on the skin, indicating a mild allergic reaction.
• Hypotension: A transient drop in blood pressure may occur, leading to a feeling of faintness.
• Hematuria: The presence of blood in the urine has been reported in rare cases following high-dose infusions.

> Warning: Stop taking Arginine and call your doctor immediately if you experience any of these serious symptoms.

• Anaphylaxis: A severe, life-threatening allergic reaction. Symptoms include swelling of the face, lips, or tongue, difficulty breathing, wheezing, and a rapid, weak pulse.
• Severe Hyperkalemia: High levels of potassium in the blood can cause life-threatening heart rhythm problems. Symptoms include muscle weakness, fatigue, and palpitations.
• Metabolic Acidosis: Arginine hydrochloride can increase the acidity of the blood. Signs include rapid, shallow breathing, confusion, and extreme lethargy.
• Extravasation Necrosis: If the intravenous fluid leaks into the surrounding tissue (extravasation), it can cause severe tissue damage or death (necrosis). If you feel burning or see significant swelling at the IV site, alert the medical staff immediately.

While Arginine is typically used for short-term diagnostic purposes, long-term oral supplementation has been associated with specific risks:

• Herpes Simplex Reactivation: There is clinical evidence suggesting that high levels of Arginine can promote the replication of the herpes simplex virus. Individuals prone to cold sores or genital herpes may experience more frequent outbreaks.
• Gout Exacerbation: Arginine may increase uric acid levels in some individuals, potentially triggering a gout attack.
• Blood Pressure Changes: Chronic use may lead to consistently lower blood pressure, which can be problematic for those already taking antihypertensive medications.

No FDA black box warnings for Arginine. However, the FDA does require prominent warnings regarding the risk of hyperchloremic metabolic acidosis and hyperkalemia in patients with renal or hepatic impairment. Additionally, the risk of severe tissue damage from extravasation is a highlighted safety concern in the prescribing information.

Report any unusual symptoms or persistent side effects to your healthcare provider. Monitoring of blood chemistry is standard practice during and after clinical administration.

Arginine is a potent metabolic agent and must be used with significant caution. It is not a simple 'vitamin' when used in clinical doses; it is a pharmacologically active substance that can profoundly alter blood chemistry. Patients with a history of electrolyte imbalances, kidney disease, or liver disease must be evaluated thoroughly before administration.

No FDA black box warnings for Arginine as of 2026.

• Allergic Reactions / Anaphylaxis Risk: Although rare, Arginine can cause severe allergic reactions. Healthcare facilities must have emergency equipment (epinephrine, oxygen, airway management) readily available during the infusion. Patients with known food allergies, particularly to protein-rich foods, should be monitored closely.
• Metabolic Acidosis: Arginine Hydrochloride contains a high concentration of chloride ions. Rapid infusion can lead to hyperchloremic metabolic acidosis, a condition where the blood becomes too acidic. This is particularly dangerous in patients with underlying respiratory or renal conditions who cannot compensate for the acid load.
• Hyperkalemia: Arginine can cause potassium to move from the inside of cells to the extracellular fluid, raising blood potassium levels. In patients with healthy kidneys, this is usually temporary. However, in patients with renal failure, this can lead to dangerous cardiac arrhythmias.
• Extravasation Risk: Arginine is a hypertonic solution (highly concentrated). If the IV needle dislodges and the fluid enters the skin tissue instead of the vein, it can cause severe irritation and tissue sloughing. The infusion site must be monitored continuously by nursing staff.

When undergoing an Arginine infusion, the following monitoring is typically required:

• Baseline Electrolytes: Blood tests for potassium, chloride, sodium, and bicarbonate before the test.
• Renal Function: Checking BUN (Blood Urea Nitrogen) and Creatinine levels to ensure the kidneys can handle the nitrogen load.
• Blood Glucose: Arginine can stimulate the release of insulin and glucagon, potentially causing fluctuations in blood sugar levels.
• Vital Signs: Continuous or frequent monitoring of heart rate and blood pressure during the 30-minute infusion.

Arginine may cause dizziness or lightheadedness immediately following an infusion. It is generally recommended that patients do not drive or operate heavy machinery for at least 2 to 4 hours after the procedure, or until they are certain they have fully recovered from any transient side effects.

Alcohol should be avoided for at least 24 hours before and after an Arginine diagnostic test. Alcohol can interfere with growth hormone secretion, potentially leading to a false-negative test result. Additionally, alcohol can exacerbate the gastrointestinal side effects of Arginine.

For diagnostic use, Arginine is a one-time dose and does not require tapering. If using Arginine as a long-term supplement for metabolic disorders, do not stop taking it suddenly without consulting your specialist, as this could lead to a rapid rise in blood ammonia levels (hyperammonemia).

> Important: Discuss all your medical conditions, especially kidney disease and heart problems, with your healthcare provider before starting Arginine.

While there are few absolute contraindications for drug combinations, Arginine should never be used in patients who are currently receiving or have recently received medications that significantly alter potassium levels unless under strict intensive care monitoring.

• Potassium-Sparing Diuretics (e.g., Spironolactone, Triamterene, Amiloride): Using these with Arginine can cause life-threatening hyperkalemia. The combination prevents the kidneys from excreting the excess potassium shifted into the blood by Arginine.

• ACE Inhibitors and ARBs (e.g., Lisinopril, Losartan): These blood pressure medications also tend to increase potassium levels. Using them alongside Arginine requires frequent electrolyte monitoring to prevent cardiac complications.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Medications like ibuprofen or naproxen can reduce renal blood flow, making it harder for the kidneys to process the chloride and nitrogen load from Arginine.
• Nitrates (e.g., Nitroglycerin, Isosorbide): Since Arginine is a precursor to nitric oxide, it can enhance the vasodilatory effects of nitrates, potentially leading to dangerously low blood pressure (hypotension).

• Antidiabetic Medications: Arginine can stimulate the release of insulin. Patients on insulin or oral hypoglycemics (like Metformin or Glyburide) may experience unexpected drops in blood sugar. Blood glucose should be monitored closely during and after Arginine administration.
• Sildenafil and other PDE5 Inhibitors: Similar to nitrates, these drugs increase nitric oxide pathways. Combining them with Arginine may cause significant drops in blood pressure and dizziness.

• High-Protein Meals: Consuming a very high-protein meal before an Arginine test can interfere with the results by altering baseline amino acid levels. Most diagnostic tests require a period of fasting (usually overnight).
• Caffeine: Caffeine can affect growth hormone levels and should be avoided on the day of a diagnostic test.

• Citrus Aurantium (Bitter Orange): May interact with the cardiovascular effects of Arginine.
• Ginkgo Biloba: May enhance the blood-thinning or vasodilatory effects of Arginine, increasing the risk of bruising or low blood pressure.
• Potassium Supplements: Any over-the-counter potassium supplement should be discontinued prior to Arginine administration to avoid hyperkalemia.

Arginine can interfere with several laboratory measurements:

• Blood Urea Nitrogen (BUN): Levels will naturally rise following Arginine administration as the body processes the nitrogen.
• Serum Creatinine: May be transiently affected.
• Electrolytes: Chloride levels will rise, and bicarbonate levels may fall, reflecting the acidifying effect of the hydrochloride salt.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter vitamins.

Arginine must NEVER be used in the following circumstances:

• Known Hypersensitivity: Any patient with a documented allergy to Arginine or any component of the formulation (such as the hydrochloride salt) should not receive the drug. Anaphylaxis is a risk.
• Severe Renal Failure: Patients with end-stage renal disease (ESRD) or significantly impaired kidney function cannot handle the nitrogen and chloride load, leading to fatal metabolic acidosis and hyperkalemia.
• Recent Myocardial Infarction (Heart Attack): A major clinical trial (the VINTAGE MI study) suggested that Arginine supplementation after a heart attack might increase the risk of death. Therefore, it is strictly contraindicated in the acute post-MI period.

Conditions requiring a careful risk-benefit analysis by a physician include:

• Mild to Moderate Renal Impairment: Requires lower doses and intense monitoring.
• Electrolyte Imbalance: Existing hyperkalemia or hyperchloremia must be corrected before Arginine is administered.
• Asthma: Arginine can potentially cause bronchoconstriction in some sensitive individuals due to its role in inflammatory pathways.
• Herpes Simplex Infection: Patients with active or frequent outbreaks should be aware that Arginine may trigger a recurrence.

There is little evidence of cross-sensitivity between Arginine and other amino acids. However, patients who are sensitive to other hydrochloride-based salts (like Lysine Hydrochloride) should be monitored for similar metabolic acidotic reactions.

> Important: Your healthcare provider will evaluate your complete medical history, including recent lab work, before prescribing or administering Arginine.

Arginine is classified as FDA Pregnancy Category B. Animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, Arginine should be used during pregnancy only if clearly needed. It is occasionally used in research for preeclampsia, but this is not an established standard of care and should only occur within a clinical trial framework.

It is not known whether Arginine is excreted in human milk. However, since it is a naturally occurring amino acid, small amounts are always present. The safety of high-dose intravenous Arginine in nursing mothers has not been established. Healthcare providers usually recommend exercising caution and potentially suspending breastfeeding for 24 hours following a diagnostic infusion.

The primary clinical use of Arginine is in the pediatric population to diagnose growth hormone deficiency. It is considered safe and effective for this purpose when dosed correctly (0.5 g/kg). However, extreme care must be taken to avoid overdosage, which can lead to severe metabolic acidosis in small children. Arginine is not approved for general 'growth promotion' in children who do not have a diagnosed deficiency.

Elderly patients are at a higher risk for adverse reactions to Arginine due to the natural decline in renal function associated with aging. There is an increased risk of hyperkalemia and fluid overload. Clinical assessments should include a review of the patient's cardiac and renal status. Dosage should be conservative, and monitoring should be more frequent than in younger adults.

In patients with a GFR (Glomerular Filtration Rate) below 30 mL/min, Arginine is generally avoided. For those with mild impairment (GFR 30-60 mL/min), the infusion rate should be slowed, and the total dose may be reduced. Dialysis can remove Arginine and correct the associated metabolic acidosis if an emergency occurs.

Patients with Child-Pugh Class B or C cirrhosis are at risk for hyperammonemia and electrolyte shifts. While Arginine is used to treat specific urea cycle defects, in the context of general liver failure, it can exacerbate hepatic encephalopathy. Use in these patients requires consultation with a hepatologist.

> Important: Special populations require individualized medical assessment and often require more intensive monitoring during treatment.

Arginine (L-arginine) is a basic amino acid with a complex pharmacological profile. Its primary clinical mechanism involves the stimulation of the anterior pituitary gland to release stored Growth Hormone (GH). This is thought to occur through the suppression of endogenous somatostatin release. Somatostatin normally acts as a 'brake' on GH release; by removing this inhibition, Arginine allows for a surge in GH levels.

Additionally, Arginine is the substrate for Nitric Oxide Synthase (NOS). This enzyme converts Arginine into L-citrulline and Nitric Oxide (NO). NO is a gas that diffuses into vascular smooth muscle cells, where it activates guanylyl cyclase, increasing cyclic GMP (cGMP) and causing profound muscle relaxation and vasodilation.

Following intravenous administration, the onset of GH stimulation is rapid, with peak GH levels typically occurring between 60 and 90 minutes. The effect is dose-dependent up to the standard 30-gram dose. The vasodilatory effects of Arginine are almost immediate but transient, lasting only as long as the infusion and for a short period thereafter. Tolerance does not typically develop with single diagnostic doses, but chronic use may lead to a down-regulation of the NO pathway.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV), ~20-25% (Oral) |

| Protein Binding | Negligible |

| Half-life | 30 to 120 minutes |

| Tmax (GH surge) | 60 to 90 minutes post-infusion |

| Metabolism | Hepatic (Arginase enzyme) |

| Excretion | Renal (<10% unchanged) |

The molecular formula for Arginine is C6H14N4O2, with a molecular weight of 174.20 g/mol. As a hydrochloride salt (the common clinical form), it is highly soluble in water. It is a white, crystalline powder that is odorless. Structurally, it contains a guanidino group, which is responsible for its basic (alkaline) properties.

Arginine is classified as a Non-Essential Amino Acid and a Diagnostic Agent. Within the EPC (Established Pharmacologic Class) system, it is recognized as an Amino Acid [EPC] and a Vasodilator [EPC]. It is also grouped with other pituitary stimulants used in endocrine challenge testing, such as Insulin and Glucagon.